Clinical Trials Browser

Phase 2/3 × INDUSTRY × nilotinib × Clear all

NCT00264160 2017-03-06

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Phase 2/3 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive